Use of Baricitenib to Maintain of Remission

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
Baricitinib a selective Janus kinase (JAK) inhibitors 1\&2 have been recognized as a potential therapeutic option in systemic lupus (SLE), also known Baricitinib, a JAK inhibitor, has demonstrated efficacy and safety in the treatment of dermatitis and arthritis 1 ; however, no JAK inhibitor studies have been conducted in lupus nephritis (LN) maintain remission to date.
Epistemonikos ID: c38787eeafa8b7dddd042edfa7669109fd8c48b0
First added on: Feb 19, 2024